TG Therapeutics (TGTX) Lowered to “Buy” at BidaskClub

BidaskClub lowered shares of TG Therapeutics (NASDAQ:TGTX) from a strong-buy rating to a buy rating in a research report released on Tuesday, April 16th, BidAskClub reports.

A number of other analysts also recently commented on the company. HC Wainwright reiterated a buy rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. Jefferies Financial Group restated a buy rating and set a $8.00 target price on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley began coverage on TG Therapeutics in a research report on Tuesday, January 8th. They set a buy rating and a $10.00 target price for the company. Cantor Fitzgerald began coverage on TG Therapeutics in a research report on Friday, March 29th. They set an overweight rating and a $17.00 target price for the company. Finally, ValuEngine downgraded TG Therapeutics from a hold rating to a sell rating in a research report on Thursday, February 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $14.07.

Shares of NASDAQ TGTX traded down $0.55 during mid-day trading on Tuesday, reaching $7.56. 1,800,626 shares of the company traded hands, compared to its average volume of 1,406,073. TG Therapeutics has a fifty-two week low of $3.32 and a fifty-two week high of $16.00.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 245.97% and a negative net margin of 98,576.14%. Research analysts expect that TG Therapeutics will post -1.63 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. lifted its holdings in shares of TG Therapeutics by 23.6% in the first quarter. Advisor Group Inc. now owns 7,850 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,500 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in shares of TG Therapeutics in the first quarter valued at about $117,000. New York State Common Retirement Fund lifted its holdings in shares of TG Therapeutics by 37.2% in the first quarter. New York State Common Retirement Fund now owns 63,100 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 17,100 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in TG Therapeutics during the first quarter worth about $291,000. Finally, Raymond James & Associates raised its holdings in TG Therapeutics by 15.6% during the first quarter. Raymond James & Associates now owns 381,437 shares of the biopharmaceutical company’s stock worth $3,067,000 after acquiring an additional 51,418 shares in the last quarter. 55.19% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: What do investors mean by earnings per share?

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.